Literature DB >> 4031386

More on nomifensine.

A Liuzzi, P G Chiodini.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031386     DOI: 10.1007/BF03350679

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  7 in total

1.  Nomifensine in hyperprolactinemic states.

Authors:  E E Müller; F Camanni; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

2.  Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

Authors:  F Iannotta; P Fachinetti; A Fachinetti; G Pinotti; L Usellini
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

3.  Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients.

Authors:  S Bansal; L A Lee; P D Woolf
Journal:  Am J Med       Date:  1981-12       Impact factor: 4.965

4.  Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects.

Authors:  O Serri; O Kuchel; N T Buu; M Somma
Journal:  J Clin Endocrinol Metab       Date:  1983-02       Impact factor: 5.958

5.  Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia.

Authors:  C B Webb; J L Thominet; H Barowsky; M Berelowitz; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1983-06       Impact factor: 5.958

6.  Prolactin-secreting adenomas in women. VII. Dopamine regulation of prolactin secretion.

Authors:  M C Martin; R I Weiner; S E Monroe; J M Roberts; V Licko; R B Jaffe
Journal:  J Clin Endocrinol Metab       Date:  1984-09       Impact factor: 5.958

7.  Nomifensine: diagnostic test in hyperprolactinemic states.

Authors:  E E Müller; A R Genazzani; S Murru
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

  7 in total
  1 in total

1.  More on nomifensine.

Authors:  A E Pontiroli; L Falsetti
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.